rHEALTH Technology Receives Notice of Allowance from US Patent Office for Multiplexed Tests in Small Sample Volumes
CAMBRIDGE, Mass., January 23, 2019 /PRWeb/ — rHEALTH LLC, an innovative digital health solutions company, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 14/682,010, entitled “Microparticle Multiplexing”, filed by its affiliate DNA Medicine Institute (DMI).
This patent application covers the addition of a length scale to hydrogel microparticles, a key advancement enabling highly multiplexed diagnostic testing in small-volume samples. A Notice of Allowance indicates that the USPTO has completed its review, and issuance of the patent is pending, expected within two months.
“In combination with our U.S. Patent 9,568,425, ‘Multicoded Analytical Nanostrips,’ this patent further strengthens protection for our technology,” said Dr. Eugene Y. Chan, Founder and CEO. “The fundamental aspects of this innovation allow our platform to measure multiple analytes from a single small-volume sample, whether at home or in a clinical setting.”
About rHEALTH
rHEALTH is a digital health solutions company creating integrated technologies that transform healthcare. Its core innovations include:
rHEALTH Diagnostic Platform – enables multiple laboratory tests from a single small-volume blood sample at the point-of-care.
SKYE Sensor – a wireless wearable providing real-time, comprehensive vital sign monitoring.
CHAS – a user-friendly mobile application supporting health management.
For more information, visit www.rhealth.com.
About DNA Medicine Institute
DNA Medicine Institute (DMI), rHEALTH’s affiliate, is a biomedical incubator dedicated to advancing patient care, alleviating human suffering, and treating disease through innovation. Supported by NASA, NIH, and the Bill & Melinda Gates Foundation, DMI leverages interdisciplinary science and engineering expertise to tackle complex biomedical challenges.
For more information, visit www.dnamedinstitute.com.
Media Contact:
John Adamou
VP, Corporate & Business Development / Media Relations
(617) 999-8395
pr@rhealth.com